NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Data completeness
7/8 — Comprehensive
JORNAY PM (methylphenidate hydrochloride) by Teva is (cns) stimulant. Approved for attention deficit hyperactivity disorder. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JORNAY PM is an extended-release oral capsule formulation of methylphenidate hydrochloride, a CNS stimulant approved in 2018 for ADHD and several off-label psychiatric indications. The exact mechanism of therapeutic action is unknown, though methylphenidate is thought to block reuptake of norepinephrine and dopamine. It is designed for evening dosing to provide symptom control throughout the following day.
$0.001BPart D
Peak5.9 years to LOEProduct is in peak revenue phase with minimal Part D penetration ($1M spend, 2,065 claims in 2023), indicating either niche positioning, market saturation by competitors, or untapped potential in the ADHD stimulant category.
Mechanism of Action
(CNS) stimulant. The exact mode of therapeutic action in ADHD is not known.
Indications (1)
Clinical Trials (11)
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Started Apr 2019
60 enrolled
Attention Deficit Hyperactivity DisorderGeneralized Anxiety DisorderSocial Anxiety Disorder+2 more
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
Started Apr 2011
299 enrolled
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Started Nov 2010
725 enrolled
Attention Deficit/Hyperactivity Disorder
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Started Jul 2009
357 enrolled
Attention Deficit Disorder With Hyperactivity
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
Started Jan 2008
33 enrolled
Prostatic NeoplasmsFatigue
Worked on JORNAY PM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.